| Patents for A61P 21 - Drugs for disorders of the muscular or neuromuscular system (23,287) |
|---|
| 06/26/1997 | WO1997011190A3 Dna construct comprising a muscle specific regulatory element for immunization or gene therapy |
| 06/26/1997 | CA2240489A1 Inhibitors of interleukin-1.beta. converting enzyme |
| 06/25/1997 | CN1152871A Methods of use for peroxynitrite decompositionc atalysts, pharmaceutical compositions therefor |
| 06/25/1997 | CN1152579A Method of preparing cyclic vasoactive peptides |
| 06/19/1997 | WO1997021811A2 Novel tyrosine kinase receptors and ligands |
| 06/19/1997 | WO1997021690A1 D-amino acid derived inhibitors of cysteine and serine proteases |
| 06/19/1997 | CA2238175A1 D-amino acid derived inhibitors of cysteine and serine proteases |
| 06/17/1997 | US5639760 Useful as muscle relaxants, sedatives, anxiolytics, anticonvulsants, and antidotes for drug overdose |
| 06/10/1997 | US5637470 Screening array using cells expressing recombinant α and β subunits of the mammalian large-conductance (maxi-K) potassium channel |
| 06/04/1997 | EP0776898A1 Process improvement in the synthesis of N-[3-(3-cyanopyrazolo [1,5-a]pyrimidin-7-yl)phenyl]-N-ethyl-acetamide |
| 05/29/1997 | WO1997018833A1 Methods of increasing lean tissue mass using ob protein compositions |
| 05/29/1997 | CA2358862A1 Methods of increasing lean tissue mass using ob protein compositions |
| 05/29/1997 | CA2236163A1 Methods of increasing lean tissue mass using ob protein compositions |
| 05/28/1997 | EP0775118A1 Benzimidazole derivatives having dopaminergic activity |
| 05/27/1997 | US5633238 Method for the treatment of schizophrenia |
| 05/21/1997 | CN1150390A Glial mitogenic factors, their preparation and use |
| 05/21/1997 | CN1150152A Process for manufacture of imidazo benzodiazepine derivatives |
| 05/21/1997 | CN1034943C Process for preparing cyclic vasoactive peptides |
| 05/14/1997 | CN1149877A Novel elastase inhibitor |
| 05/09/1997 | WO1997016185A2 A pharmaceutical composition for the treatment of autoimmune diseases |
| 05/07/1997 | EP0771198A1 Dihydro-2,3-benzodiazepine derivatives |
| 05/07/1997 | EP0771191A1 Immunological activity of rhamnolipids |
| 05/07/1997 | EP0238553B1 Method of treating catabolic dysfunction |
| 05/07/1997 | CN1148982A Sikang Shennong Yangsheng Health-care pellet |
| 05/02/1997 | EP0770395A1 Use of botulinum toxins for treating headache |
| 05/02/1997 | EP0769957A1 Methods for treating motor deficits |
| 05/01/1997 | WO1997015304A1 Use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine for preparing drugs for treating amyotrophic lateral sclerosis |
| 04/29/1997 | US5624941 Pyrazole derivatives, method of preparing them and pharmaceutical compositions in which they are present |
| 04/23/1997 | EP0769006A1 Small molecule inhibitors of rotamase enzyme activity |
| 04/23/1997 | EP0651754B1 K-252a DERIVATIVES |
| 04/23/1997 | CN1148337A Compound active at a novel site on receptor-operated calcium channels usefull for treatment of neurological disorders and diseases |
| 04/22/1997 | US5622721 Dosage forms of risedronate |
| 04/17/1997 | WO1997013504A1 Pharmaceutical compositions containing hydroximic acid derivatives |
| 04/16/1997 | EP0768312A2 Bis-Staurosporine and K-252a derivatives |
| 04/16/1997 | EP0768310A1 Process for the production of imidazo-benzodiazepine derivatives |
| 04/16/1997 | CN1147767A Use of serotonin antagonists (5HT3) for treating fibromyalgia |
| 04/15/1997 | US5620978 Nervous system disorders |
| 04/10/1997 | WO1997012619A1 Method of treating the navicular disease in horses |
| 04/09/1997 | EP0767170A1 Novel 4,6-diarylpyrimidine derivatives and salts thereof |
| 04/09/1997 | EP0666912B1 Modified ciliary neurotrophic factors |
| 04/08/1997 | US5618537 Plant-based medicaments for increasing the tone and modulating the tone of the smooth muscular organ |
| 03/27/1997 | WO1997011190A2 Dna construct comprising a muscle specific regulatory element for immunization or gene therapy |
| 03/27/1997 | WO1997010823A1 5-ht3 receptor antagonists for dyskinesia |
| 03/27/1997 | CA2231887A1 5-ht3 receptor antagonists for dyskinesia |
| 03/27/1997 | CA2231806A1 Dna construct comprising a muscle specific regulatory element for immunization or gene therapy |
| 03/25/1997 | US5614649 Treatment of muscular disorders, substituted guanidines |
| 03/25/1997 | US5614547 Small molecule inhibitors of rotamase enzyme |
| 03/25/1997 | US5614517 Treatment of neurological disorders influenced by gamma-aminobutyric acid receptors |
| 03/19/1997 | EP0762885A1 Glial mitogenic factors, their preparation and use |
| 03/13/1997 | WO1997009314A1 Novel 1-ar(alk)yl-imidazolin-2-ones containing a disubstituted amine radical in the 4th position, having an anti-convulsive effect, and process for their production |
| 03/12/1997 | EP0662081B1 Ureido-acetamide derivatives, preparation thereof and drugs containing same |
| 03/12/1997 | EP0627919B1 Application of 2-amino 6-trifluoromethoxy benzothiazole (riluzole) for obtaining a drug useful in the treatment of motor neuron diseases |
| 03/12/1997 | CN1144687A Medicinal powder for treatment of facial paralysis |
| 03/11/1997 | CA2015505C Polyamines and polypeptides useful as antagonists of excitatory amino acid neurotransmitters and/or as blockers of calcium channels |
| 03/06/1997 | DE19532668A1 Neue, antikonvulsiv wirkende 1-Ar(alk)yl-imidazolin-2-one, die in 4-Stellung einen disubstituierten Amin-Rest enthalten, und Verfahren zu deren Herstellung New anticonvulsive action 1-ar (alk) yl-imidazolin-2-ones which contain in the 4-position is disubstituted amine radical, and processes for their preparation |
| 03/05/1997 | EP0759983A1 Dna encoding the beta subunit of a mammalian "maxi-k" potassium channel |
| 03/05/1997 | EP0759978A1 Neurotransmitter transporter |
| 03/05/1997 | EP0759910A1 Acid amide derivatives and process for the preparation thereof |
| 03/04/1997 | US5607967 Treatment of alzheimer's disease with 5-(tetradecyloxy)-2-furan carboxylic acid |
| 03/04/1997 | US5607936 Useful in treatment of respiratory diseases |
| 02/27/1997 | WO1997007198A2 Dna sequences and secreted proteins encoded thereby |
| 02/27/1997 | CA2229208A1 Dna sequences and secreted proteins encoded thereby |
| 02/26/1997 | EP0759025A1 Amide derivatives and their therapeutic use |
| 02/26/1997 | EP0758892A1 Methods of use for peroxynitrite decomposition catalysts, pharmaceutical compositions therefor |
| 02/25/1997 | US5605907 Useful as a preventive and therapeutic agent for diseases against which a potassium channel opening action is efficacious |
| 02/20/1997 | WO1997006242A1 Recombinant c-proteinase and processes, methods and uses thereof |
| 02/20/1997 | CA2229044A1 Recombinant c-proteinase and processes, methods and uses thereof |
| 02/18/1997 | US5604223 Treating epilepsy, nervous system disorder |
| 02/11/1997 | US5602257 Reacting piperidone aminal with nicotinic acid derivative to form aminal nicotinoyl piperidone salt; forming anabaseine salt |
| 02/11/1997 | US5602152 Benzoxepines |
| 02/11/1997 | US5602134 Useful for treating animals suffering from congestive heart failure |
| 02/11/1997 | US5601839 Triacetin as a penetration enhancer for transdermal delivery of a basic drug |
| 02/06/1997 | WO1997004093A1 Nucleotide and peptide sequences for treating myasthenia |
| 02/06/1997 | WO1997003687A1 SOLUBLE LYMPHOTOXIN-β RECEPTORS AND ANTI-LYMPHOTOXIN RECEPTOR AND LIGAND ANTIBODIES, AS THERAPEUTIC AGENTS FOR THE TREATMENT OF IMMUNOLOGICAL DISEASE |
| 02/06/1997 | CA2227477A1 Soluble lymphotoxin-.beta. receptors and anti-lymphotoxin receptor and ligand antibodies, as therapeutic agents for the treatment of immunological disease |
| 02/04/1997 | US5599936 Isoindolinone derivative, preparation thereof and pharmaceutical compositions containing same |
| 02/04/1997 | US5599830 Sulphorous derivatives of imidazole and their use as medicaments |
| 01/30/1997 | WO1997002833A1 A stabilized pharmaceutical formulation comprising a growth hormone and a peptide comprising at least, one basic amino acid residue and at least one acid amino acid residue |
| 01/30/1997 | WO1996035805A3 Tripeptidylpeptidase inhibitors |
| 01/30/1997 | CA2226553A1 A stabilized pharmaceutical formulation comprising a growth hormone and a peptide comprising at least, one basic amino acid residue and at least one acid amino acid residue |
| 01/29/1997 | CN1141297A Pyrazolopyrimidines and pyrrolopyrimidines for treatment of neuronal and other disorders |
| 01/23/1997 | WO1997002342A1 Recombinant antibodies from a phage display library, directed against a peptide-mhc complex |
| 01/23/1997 | WO1997002269A1 Condensed thiazole derivatives, having 5-ht receptor affinity |
| 01/23/1997 | CA2222725A1 Therapeutic agents |
| 01/22/1997 | EP0754687A1 Phenyl heterocycles as cyclooxygenase-2 inhibitors |
| 01/22/1997 | EP0698024B1 [1,2,4]TRIAZOLO [4,3-a]QUINOXALINE COMPOUNDS, THEIR PREPARATION AND USE |
| 01/16/1997 | WO1997001570A1 Colchicine derivatives, the use thereof and formulations containing them |
| 01/15/1997 | EP0752862A1 Use of biopolymers for the muscle treatment |
| 01/14/1997 | US5593992 Cytokine inhibitors |
| 01/14/1997 | US5593991 Imidazole compounds, use and process of making |
| 12/31/1996 | US5589475 Benzodiazepine treatment |
| 12/27/1996 | EP0500853B1 Phenylethanolamines, drugs containing these compounds, and a method of preparing them |
| 12/19/1996 | WO1996040633A1 Small molecule inhibitors of rotamase enzyme activity |
| 12/17/1996 | US5585358 Derivatives of valproic acid amides and 2-valproenoic acid amides, method of making and use thereof as anticonvulsant agents |
| 12/17/1996 | US5585089 Humanized immunoglobulins |
| 12/11/1996 | CN1137753A Epibatidine and derivatives thereof as cholinergic receptor agonists and antagonists |
| 12/10/1996 | US5583117 Acylated uridine and cytidine for elevating tissue uridine and cytidine |
| 12/04/1996 | CN1137274A 6-oxo-nucleosides useful as immunosuppressants |
| 12/04/1996 | CN1136960A Polyamines and polypeptides useful as antagonisis of excitatory amino acid neurotransmitiers and/or as blockers of calcium channels |
| 11/27/1996 | EP0743855A1 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/nmda receptor |